An overview of the mechanism of action of the monoclonal antibody vedolizumab

T Wyant, E Fedyk, B Abhyankar - Journal of Crohn's and Colitis, 2016 - academic.oup.com
Vedolizumab is a novel therapeutic monoclonal antibody recently approved for the treatment
of moderately to severely active ulcerative colitis and Crohn's disease in adults who have …

An Overview of the Mechanism of Action of the Monoclonal Antibody Vedolizumab

T Wyant, E Fedyk, B Abhyankar - Journal of Crohn's & …, 2016 - pubmed.ncbi.nlm.nih.gov
Vedolizumab is a novel therapeutic monoclonal antibody recently approved for the treatment
of moderately to severely active ulcerative colitis and Crohn's disease in adults who have …

An Overview of the Mechanism of Action of the Monoclonal Antibody Vedolizumab.

T Wyant, E Fedyk, B Abhyankar - Journal of Crohn's & Colitis, 2016 - europepmc.org
Vedolizumab is a novel therapeutic monoclonal antibody recently approved for the treatment
of moderately to severely active ulcerative colitis and Crohn's disease in adults who have …

[引用][C] An Overview of the Mechanism of Action of the Monoclonal Antibody Vedolizumab

T Wyant, E Fedyk, B Abhyankar - Journal of Crohn's and Colitis, 2016 - cir.nii.ac.jp
An Overview of the Mechanism of Action of the Monoclonal Antibody Vedolizumab | CiNii
Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ …

An Overview of the Mechanism of Action of the Monoclonal Antibody Vedolizumab.

T Wyant, E Fedyk, B Abhyankar - Journal of Crohn's & Colitis, 2016 - search.ebscohost.com
Vedolizumab is a novel therapeutic monoclonal antibody recently approved for the treatment
of moderately to severely active ulcerative colitis and Crohn's disease in adults who have …